Avsnitt
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss obesity as a disease.
-
In this eight part video series, JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, and Ania Jastreboff, MD, PhD, discuss obesity. In this discussion, they review the language around obesity and taking care to meet patients where they are.
-
Saknas det avsnitt?
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this video, they discuss how cardiologists can use medications to treat obesity.
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss concerns around the range of popular obesity medications today.
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss patients with obesity and society's view of obesity, as well as the role of the CV physician in shifting the culture around obesity.
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss if patients can be healthy and have obesity, as well as the many impacts that obesity can have on patients.
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss how and why cardiovascular physicians can and should learn about the medications to treat patients with obesity.
-
Harlan M. Krumholz, MD, SM, Editor-in-Chief of JACC, speaks with Ania Jastreboff, MD, PhD, in this 8 part video series. In this portion, they discuss why cardiologists should care about obesity, and how JACC is raising awareness of treating obesity and helping patients.
-
In this episode, Dr. Valentin Fuster discusses five key studies from the January 2025 JACC issue, covering advancements in coronary angioplasty, revascularization strategies for STEMI, machine learning for ICD patient outcomes, thromboxane’s link to heart failure, and TAVR valve types and anesthesia approaches. These studies provide valuable insights into improving cardiovascular care and treatment.
-
In this episode, Dr. Valentin Fuster discusses the findings of a major randomized trial examining the use of drug-coated balloons (DCB) in treating side branch stenosis during coronary bifurcation procedures. The study suggests that DCBs offer better one-year outcomes compared to non-coated balloons, showing a significant reduction in myocardial infarction rates, but highlights ongoing challenges in managing bifurcation lesions, especially considering the high cost and potential risks.
-
In this episode, Dr. Valentin Fuster discusses a comprehensive network meta-analysis published in JACC, which evaluates the optimal strategy for complete revascularization in patients with STEMI and multi-vessel disease. The study concludes that both immediate and staged complete revascularization improve patient outcomes over partial revascularization, with no significant advantage between angiographic and functional guidance, suggesting that angiographic guidance alone may be sufficient in clinical practice.
-
In this episode, Dr. Valentin Fuster discusses a groundbreaking study that uses machine learning to predict mortality and hospitalization risks in patients with implantable cardioverter defibrillators (ICDs). By leveraging large datasets and time-varying ICD data, the study developed a robust predictive model, though challenges remain regarding data gaps and its applicability to diverse patient populations.
-
In this episode, Dr. Valentin Fuster discusses a study published in the Journal of the American College of Cardiology examining the link between urinary thromboxane B2 metabolites and the risk of developing heart failure. The research suggests that high levels of these metabolites, potentially from the myocardium or other organs rather than platelets, are associated with an increased risk of heart failure, offering a potential new biomarker for early detection and targeted prevention strategies.
-
In this episode, Dr. Valentin Fuster discusses the five-year results of the SOFT TAVI trial, which compared self-expanding and balloon-expanding valves for transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis. The findings reveal similar long-term outcomes for both valve types and anesthesia strategies, with subtle differences in stroke rates and pacemaker implantations, emphasizing the growing safety and efficacy of conscious sedation in TAVR procedures.
-
In this episode, Dr. Valentin Fuster highlights five cutting-edge cardiology studies from the December 2024 issue of JACC, covering topics such as cardiac MRI's role in predicting sudden cardiac events in Fontan patients, the impact of oxidized phospholipids on calcific aortic valve disease, and the effects of renal and liver function on outcomes after tricuspid valve repair. With insights on mortality risks from influenza in heart failure patients and the outcomes of anatomical versus physiological repair for congenital heart defects, the episode offers a comprehensive look at critical advancements in cardiovascular care.
-
In this episode, Dr. Valentin Fuster discusses a groundbreaking study on cardiac MRI predictors of arrhythmic sudden cardiac events in patients with Fontan circulation, highlighting key risk factors for these life-threatening incidents. The study, part of the multi-center FORCE registry, reveals significant findings, including the impact of clinical status and ventricular function, while emphasizing the importance of large-scale research in improving outcomes for single ventricle patients.
-
In this podcast, Dr. Valentin Furster discusses a groundbreaking study on the role of oxidized phospholipids in calcific aortic valvular disease, highlighting their significant association with disease prevalence and progression. The findings suggest that targeting oxidized phospholipids, not just the Lp(a) particle, could offer a promising new therapeutic approach to treat this condition.
-
In this podcast, Dr. Valentin Fuster discusses a study on the impact of renal and liver function on clinical outcomes following tricuspid valve transcatheter H2O repair in patients with severe tricuspid regurgitation. While the study found no significant differences in organ function between repair and control groups at 12 months, successful repairs showed small but favorable improvements in kidney and liver function, suggesting potential long-term benefits in reducing heart failure hospitalizations and mortality.
-
In this podcast, Dr. Valentin Fuster discusses a study on the significant impact of seasonal influenza on mortality and hospitalizations among patients with heart failure. The research highlights that influenza is responsible for substantial excess deaths and hospitalizations in this vulnerable group, emphasizing the need for better vaccination uptake and preventive measures to reduce these risks.
-
In this podcast, Dr. Valentin Fuster discusses a study on the long-term outcomes of two surgical approaches—anatomic and physiologic repair—for congenitally corrected transposition of the great arteries. The findings suggest that while the complex anatomic repair offers better survival and reintervention-free outcomes, patient selection is crucial, with careful consideration needed, especially for asymptomatic infants or those with preoperative pulmonary artery banding.
- Visa fler
